Find a Clinical Trial

Showing 1 - 10 of 306 Trials

A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery

Principal Investigator:

Eileen Patricia Connolly, MD

Contact Number:

212-342-5162

NCT Number:

NCT01570998

Population:

Adult

Phase:

IV

The purpose of this study is to evaluate the use of targeted intraoperative radiation therapy (IORT), where radiation is given one time during surgery. This study is being done to see if there are any differences between women who receive standard radiation after surgery versus those who have IORT. IORT is given during surgery after the tumor has been removed. The IORT device, called Intrabeam Device®, is FDA approved to be used in all parts of the body to deliver radiation. It can deliver radiation therapy accurately targeted to the area of the breast where the tumor has been removed...
Head Start 4: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed By

Principal Investigator:

James Hinkley Garvin Jr, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02875314

Population:

Pediatrics

Phase:

IV

This is a prospective randomized clinical trial, to determine whether dose- intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival (OS). The study population will be high-risk patients (non-Wnt and non-Shh sub-groups) with medulloblastoma, and for all patients with central nervous system (CNS) embryonal tumors completing Head Start 4 Induction. This study will further determine whether the additional labor intensity (duration of hospitalizations and short-term and long-term morbidities) associated...
A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Principal Investigator:

Bret Taback, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT01901094

Population:

Adult

Phase:

III

Patients with your type of breast cancer usually have neoadjuvant (which means “given before surgery) chemotherapy followed by breast and arm pit surgery to remove any remaining breast cancer. The lymph nodes in the arm pit are examined during surgery and if there is still cancer in the lymph nodes, then the majority of lymph nodes in the arm pit are removed. The purpose of this study is to examine whether removing some of the lymph nodes from the arm pit, but not removing them all followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes...
ANBL1232: Utilizing Response and Biology Risk Factors to guide Therapy in Patients with Non-Risks Neuroblastoma

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT02176967

Population:

Pediatrics

Phase:

III

This phase III study is looking at whether using certain risk factors and biomarkers (proteins and/or gene changes in tumor cells) to determine how much treatment a younger patient with non-high risk neuroblastoma should receive will allow for a decrease in treatment for these patients while still curing their neuroblastoma. For some patients, this may include no treatment and only close observation. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. This may help to avoid some of the risks and side effects related to...
AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT03067181

Population:

Pediatrics/Adult

Phase:

III

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Are you Eligible? (Inclusion Criteria)...
ACCL1633 - The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT03057054

Population:

Pediatrics/Adult

Phase:

III

This randomized clinical trial is examining how well Lactobacillus plantarum works in preventing acute graft versus host disease in children who are undergoing stem cell transplant. Lactobacillus plantarum may help prevent the development of gastrointestinal graft versus host disease in children, adolescents, and young adults undergoing donor stem cell transplant. Are you Eligible? (Inclusion Criteria) Between 2 and 25 years of age Receiving an stem cell transplant from a donor No previous history of stem cell transplant or cellular therapy Patients must also meet all other eligibility...
AALL1631: International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) testing Imatinib in combination with two different cytotoxic chemotherapy backbones

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT03007147

Population:

Pediatrics/Adult

Phase:

III

This phase 3 study is examining the best treatments for Philadelphia chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). The goal of this study is to see if using a less toxic chemotherapy regimen in combination with Imatinib can effectively treat standard risk Ph+ ALL. Patients with high risk Ph+ ALL will receive more intensive chemotherapy followed by stem cell transplant. Are you Eligible? (Inclusion Criteria) must be at least greater than 1 year and less than 21 years of age Patients must be newly diagnosed Patients must also meet all eligibility criteria as outlined in the study...
ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping

Principal Investigator:

Bret Taback, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03927027

Population:

Adult

Phase:

III

The purpose of this study is to compare usual lymph node surgery to an added procedure during the surgery to help surgeons see the lymph node system better. During usual surgery, the lymph node system may be disrupted, which can cause swelling in the arm. This research study will use a new lymph node surgery technique to look at how fluid drains through the lymph node system in your upper arm. This new procedure could reduce the chance of developing arm swelling. But, it could also cause side effects. There will be about 516 people taking part in this study. This study will help the study...
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03907488

Population:

Pediatrics/Adult

Phase:

III

This study is being done to answer the following question: Standard therapy for advance stage Hodgkin Lymphoma has recently improved with the addition of brentuximab vedotin to standard chemotherapy. This study is being performed to understand if adding the study drug nivolumab to standard chemotherapy will extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and for up to ten years after you stop taking these drugs to...
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb

Principal Investigator:

Divaya Bhutani, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04504825

Population:

Adult

Phase:

III

The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Are you diagnosed with stage 3b of AL amyloidosis? Have you not receive treatment for your disease?

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages